Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00105040
Status:
COMPLETED
Last Update Posted:
2015-03-02
First Post:
2005-03-03
Brief Title:
A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
A 19-week Randomized Double-blind Multicenter Placebo-controlled Safety Study to Evaluate the Cognitive and Neuropsychological Effects of Levetiracetam 20 - 60 mgkgDay Divided in Twice Daily Dosing as Adjunctive Treatment in Children 4 - 16 Years Old Inclusive With Refractory Partial Onset Seizures
Status:
COMPLETED
Status Verified Date:
2015-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A 12-week Evaluation Period will be used to characterize potential cognitive and neuropsychological effects of LEV 20 - 60 mgkgday as adjunctive treatment in children 4 - 16 years old inclusive with refractory partial onset seizures when compared to adjunctive treatment with placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2014-004396-23 | EUDRACT_NUMBER | None | None |